Literature DB >> 9755246

Neither intestinal sequestration of bile acids nor common bile duct ligation modulate the expression and function of the rat ileal bile acid transporter.

M Arrese1, M Trauner, R J Sacchiero, M W Crossman, B L Shneider.   

Abstract

The regulatory responses of bile acid (BA) transport in the terminal ileum to perturbations in BA homeostasis are complex, and conflicting results have been reported by different investigators. These studies were designed to examine the response of this system to a reduction in ileal bile salt concentrations at both a functional and molecular level. Common bile duct ligation (BDL) or feeding of a novel bile acid-binding compound, GT31-104HB, for 7 days were used to reduce ileal apical membrane bile salt flux. Apical bile acid transport function was assessed by examining sodium-dependent uptake of [3H]-taurocholate (TC) into brush border membrane vesicles (BBMV). Expression of the apical sodium-dependent bile acid transporter (ASBT) and the ileal lipid-binding protein (ILBP) were assessed by Western blotting with quantitation using [125I]-labeled secondary antibody and a phosphorimager. Neither common BDL nor intestinal sequestration of BA led to a change in ileal bile acid transport function or the expression of the ASBT or the ILBP. These results indicate that a reduction in presentation of bile salts to the apical surface of the terminal ileum does not modulate the expression of the genes involved in their transport.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755246     DOI: 10.1002/hep.510280424

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  19 in total

1.  Cholesterol-lowering effects of guar gum: changes in bile acid pools and intestinal reabsorption.

Authors:  S Moriceau; C Besson; M A Levrat; C Moundras; C Rémésy; C Morand; C Demigné
Journal:  Lipids       Date:  2000-04       Impact factor: 1.880

Review 2.  FXR signaling in the enterohepatic system.

Authors:  Tsutomu Matsubara; Fei Li; Frank J Gonzalez
Journal:  Mol Cell Endocrinol       Date:  2012-05-17       Impact factor: 4.102

3.  Apical sodium-dependent bile acid transporter upregulation is associated with necrotizing enterocolitis.

Authors:  Melissa D Halpern; Jörn-Hendrik Weitkamp; Sarah K Mount Patrick; Holly J Dobrenen; Ludmila Khailova; Hernan Correa; Bohuslav Dvorak
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-07-08       Impact factor: 4.052

Review 4.  Bile acid transporters in health and disease.

Authors:  A Kosters; S J Karpen
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

Review 5.  Does abnormal bile acid metabolism contribute to NEC?

Authors:  Melissa D Halpern; Bohuslav Dvorak
Journal:  Semin Perinatol       Date:  2008-04       Impact factor: 3.300

6.  Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration.

Authors:  A Lanzini; M G De Tavonatti; B Panarotto; S Scalia; A Mora; F Benini; O Baisini; F Lanzarotto
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

Review 7.  Bile acid transporters.

Authors:  Paul A Dawson; Tian Lan; Anuradha Rao
Journal:  J Lipid Res       Date:  2009-06-04       Impact factor: 5.922

Review 8.  Nuclear receptors in bile acid metabolism.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Drug Metab Rev       Date:  2013-02       Impact factor: 4.518

9.  Differential expression of cholangiocyte and ileal bile acid transporters following bile acid supplementation and depletion.

Authors:  N-Sertac Kip; Konstantinos-N Lazaridis; Anatoliy-I Masyuk; Patrick-L Splinter; Robert-C Huebert; Nicholas-F LaRusso
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

Review 10.  The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships.

Authors:  J Geyer; T Wilke; E Petzinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-16       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.